Role of magnesium supplementation in the treatment of depression: A randomized clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Several studies have looked at the association between magnesium and depression, yet its role in symptom management is unclear.

The primary outcome was the net difference in the change in depression symptoms from baseline to the end of each treatment period.

Who Took Part

The study group was 126 adults.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label and crossover.

The adults were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

Each person switched between Vitamin D, K2, Magnesium and Zinc and the comparison at some point, usually with a gap in between.

What Was Measured

The primary outcome was the net difference in the change in depression symptoms from baseline to the end of each treatment period.

Secondary outcomes included changes in anxiety symptoms as well as adherence to the supplement regimen, appearance of adverse effects, and intention to use magnesium supplements in the future.

PubMed files the paper under topics including Antidepressive Agents, Depressive Disorder and Magnesium Chloride.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Vitamin D, K2, Magnesium and Zinc in 126 adults.

The publication is from 2017 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.